Clinical trials
Completed Phase 1 Endometrial Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 5 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 85 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 9 |
| M.D. Anderson Cancer Center | 3 |
| UNC Lineberger Comprehensive Cancer Center | 3 |
| Xencor, Inc. | 3 |
| GlaxoSmithKline | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Mayo Clinic | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Regeneron Pharmaceuticals | 2 |
| University of Chicago | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Endometrial Neoplasms | 85 |
| Uterine Cervical Neoplasms | 38 |
| Breast Neoplasms | 35 |
| Ovarian Neoplasms | 34 |
| Fallopian Tube Neoplasms | 28 |
| Carcinoma, Non-Small-Cell Lung | 26 |
| Carcinoma, Ovarian Epithelial | 23 |
| Stomach Neoplasms | 22 |
| Neoplasms | 21 |
| Pancreatic Neoplasms | 20 |
Trials
Showing 1 to 25 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.